Or is the due to the fact that perhaps they may not be as well invested and prepared financially as compared to other pharma companies? BD
After coming up with a billion-dollar program to encourage the growth of the state's biotech industry, you'd think that BIO and the biopharma biz would be giving great bear hugs to Massachusetts lawmakers. Instead, GSK wrote a letter to the governor castigating the bill for demonstrating "a strong anti-biopharmaceutical streak." And BIO complained that the bill included a provision that threatened research as well as patient treatment.
Are Mass. lawmakers 'anti-biopharmaceutical'? - FierceBiotech
0 comments :
Post a Comment